ALCAM and neoplasm: Overexpressed in a number of epithelial tumors and suggested to be an important prognostic marker of tumor progression [44], CD166 (i.e. ALCAM) appears to further segregate TG from NTG cells when used in combination with ESA and CD44 [30].